GSA Capital Partners LLP Purchases New Shares in Collegium Pharmaceutical, Inc. $COLL

GSA Capital Partners LLP acquired a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the third quarter, Holdings Channel reports. The fund acquired 22,285 shares of the specialty pharmaceutical company’s stock, valued at approximately $780,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Federated Hermes Inc. boosted its stake in shares of Collegium Pharmaceutical by 67.0% in the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock worth $31,000 after buying an additional 350 shares during the last quarter. CWM LLC increased its position in shares of Collegium Pharmaceutical by 453.9% during the 2nd quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 1,153 shares during the last quarter. Hantz Financial Services Inc. raised its stake in shares of Collegium Pharmaceutical by 137.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock worth $60,000 after purchasing an additional 993 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Collegium Pharmaceutical by 744.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock worth $73,000 after buying an additional 2,190 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its holdings in shares of Collegium Pharmaceutical by 304.6% in the 2nd quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock worth $90,000 after buying an additional 2,294 shares during the last quarter.

Collegium Pharmaceutical Stock Down 0.4%

Collegium Pharmaceutical stock opened at $45.00 on Friday. The firm has a 50 day simple moving average of $46.97 and a 200 day simple moving average of $41.71. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71. Collegium Pharmaceutical, Inc. has a 1-year low of $23.23 and a 1-year high of $50.79. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of 27.95 and a beta of 0.64.

Analysts Set New Price Targets

COLL has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $60.00 price objective (up previously from $46.00) on shares of Collegium Pharmaceutical in a report on Friday, January 9th. Truist Financial set a $58.00 price target on shares of Collegium Pharmaceutical in a research note on Tuesday, February 10th. Barclays dropped their price objective on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a research note on Friday, January 9th. Needham & Company LLC raised their target price on Collegium Pharmaceutical from $48.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research report on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $53.40.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, Director Rita J. Balice-Gordon sold 3,650 shares of Collegium Pharmaceutical stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $47.03, for a total transaction of $171,659.50. Following the completion of the transaction, the director owned 52,629 shares of the company’s stock, valued at $2,475,141.87. The trade was a 6.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Scott Dreyer sold 17,600 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $48.17, for a total value of $847,792.00. Following the sale, the executive vice president owned 103,613 shares in the company, valued at approximately $4,991,038.21. This represents a 14.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.51% of the stock is currently owned by insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.